XNCR: Xencor, Inc.
About
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Current Value
$23.621 Year Return
Current Value
$23.621 Year Return
Key Details
Market Cap
$1.65B
P/E Ratio
-7.38
1Y Stock Return
27.73%
1Y Revenue Growth
-41.37%
Dividend Yield
0.00%
Price to Book
2.3
Strategies that include XNCR
Stock's related to XNCR
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| RLAY | 56.75% | $803.44M | -39.70% | 0.00% |
| BEAM | 47.92% | $2.09B | -9.52% | 0.00% |
| PGEN | 44.07% | $228.91M | -28.00% | 0.00% |
| RXRX | 43.83% | $1.80B | -4.13% | 0.00% |
| ALB | 43.12% | $12.51B | -15.60% | 1.50% |
| TECH | 43.09% | $10.55B | +4.49% | 0.48% |
| CNDT | 42.42% | $569.21M | +20.27% | 0.00% |
| PRTA | 42.22% | $756.01M | -56.52% | 0.00% |
| ACLX | 41.75% | $4.74B | +69.19% | 0.00% |
| WRBY | 40.82% | $2.75B | +120.67% | 0.00% |
| RCKT | 40.45% | $1.20B | -39.83% | 0.00% |
| SDGR | 39.99% | $1.38B | -35.46% | 0.00% |
| KROS | 39.68% | $2.17B | +73.87% | 0.00% |
| ATNM | 39.66% | $44.30M | -67.05% | 0.00% |
| ALEC | 39.51% | $377.04M | -19.46% | 0.00% |
| PLRX | 39.32% | $778.32M | -9.55% | 0.00% |
| NTLA | 39.04% | $1.44B | -50.35% | 0.00% |
| DDD | 38.71% | $402.06M | -35.13% | 0.00% |
| RCUS | 38.70% | $1.33B | +5.07% | 0.00% |
| BLDP | 38.06% | $398.23M | -61.89% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BACK | -0.09% | $1.76M | -32.90% | 0.00% |
| ROL | 0.10% | $23.98B | +23.53% | 1.25% |
| PULM | -0.10% | $19.83M | +202.98% | 0.00% |
| LFVN | -0.14% | $169.84M | +130.61% | 1.10% |
| TDS | 0.15% | $3.56B | +63.43% | 1.43% |
| PRT | -0.15% | $48.72M | -16.56% | 10.33% |
| SCKT | -0.21% | $10.88M | +15.32% | 0.00% |
| IMNN | 0.25% | $10.02M | -22.89% | 0.00% |
| CHKP | 0.29% | $19.20B | +20.74% | 0.00% |
| JNPR | 0.40% | $11.61B | +30.55% | 2.49% |
| SBUX | 0.43% | $111.45B | -5.15% | 2.37% |
| NAPA | 0.43% | $1.63B | +9.61% | 0.00% |
| TH | 0.44% | $839.02M | -24.49% | 0.00% |
| TEM | 0.45% | $8.50B | 0.00% | 0.00% |
| LW | -0.52% | $10.70B | -23.51% | 1.93% |
| CEG | 0.55% | $73.37B | +91.48% | 0.59% |
| CARV | -0.55% | $8.48M | -8.79% | 0.00% |
| KGS | -0.59% | $3.37B | +110.22% | 4.11% |
| ACGL | -0.63% | $36.00B | +16.84% | 0.00% |
| NNVC | 0.67% | $19.66M | +25.69% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| COR | -12.44% | $47.48B | +21.20% | 0.86% |
| STG | -10.42% | $35.67M | +7.92% | 0.00% |
| CHD | -9.35% | $27.18B | +19.50% | 1.03% |
| MANU | -9.30% | $2.88B | -9.41% | 0.00% |
| GME | -9.19% | $11.76B | +119.68% | 0.00% |
| CME | -9.07% | $82.76B | +9.21% | 1.98% |
| LITB | -8.47% | $35.48M | -75.45% | 0.00% |
| AXON | -8.33% | $46.53B | +167.14% | 0.00% |
| FTNT | -8.13% | $69.59B | +72.67% | 0.00% |
| RSG | -7.85% | $66.05B | +31.79% | 1.04% |
| PRPO | -6.20% | $9.10M | -13.65% | 0.00% |
| HUSA | -6.17% | $16.69M | -11.56% | 0.00% |
| ADBE | -5.38% | $219.93B | -18.23% | 0.00% |
| MCK | -5.37% | $78.15B | +35.51% | 0.42% |
| K | -5.20% | $27.77B | +52.50% | 2.79% |
| RNR | -5.20% | $13.74B | +23.09% | 0.58% |
| DBX | -5.12% | $8.26B | -4.51% | 0.00% |
| CBOE | -4.91% | $21.46B | +15.84% | 1.11% |
| CYD | -4.07% | $364.46M | -2.94% | 4.26% |
| CLX | -4.01% | $20.81B | +20.66% | 2.88% |
ETF's related to XNCR
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 54.14% | $6.58B | 0.35% |
| PBE | 51.48% | $258.53M | 0.58% |
| IBB | 51.28% | $6.66B | 0.45% |
| GNOM | 50.21% | $70.59M | 0.5% |
| IWC | 49.50% | $933.99M | 0.6% |
| PTH | 48.51% | $143.31M | 0.6% |
| RSPA | 47.67% | $273.87M | 0% |
| FBT | 46.36% | $1.11B | 0.56% |
| ARKG | 46.13% | $1.13B | 0.75% |
| VTWO | 44.47% | $12.38B | 0.1% |
| IWO | 44.44% | $12.56B | 0.24% |
| IWM | 44.39% | $75.73B | 0.19% |
| XPH | 44.15% | $157.87M | 0.35% |
| NUSC | 44.14% | $1.27B | 0.31% |
| ESML | 44.11% | $1.90B | 0.17% |
| ISCG | 43.91% | $640.00M | 0.06% |
| FXH | 43.43% | $1.15B | 0.62% |
| PINK | 43.15% | $161.15M | 0.5% |
| FSMD | 43.14% | $583.89M | 0.15% |
| VXF | 43.02% | $21.54B | 0.06% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| ULST | -0.08% | $535.47M | 0.2% |
| CANE | -0.24% | $17.72M | 0.29% |
| HIGH | -0.71% | $302.78M | 0.51% |
| DBA | 0.74% | $755.88M | 0.93% |
| AGZD | 0.84% | $142.76M | 0.23% |
| BOXX | 0.96% | $4.43B | 0.1949% |
| KRBN | -1.25% | $242.47M | 0.85% |
| GBIL | 1.34% | $5.60B | 0.12% |
| FLRN | 1.50% | $2.33B | 0.15% |
| DBO | -1.62% | $217.57M | 0.77% |
| BILZ | 1.63% | $563.02M | 0.14% |
| DBE | -1.67% | $50.13M | 0.77% |
| HDRO | -1.90% | $164.26M | 0.3% |
| COMT | 1.95% | $829.06M | 0.48% |
| TPMN | 2.03% | $40.60M | 0.65% |
| SHV | 2.22% | $18.13B | 0.15% |
| KCCA | -2.50% | $220.51M | 0.87% |
| GSG | 2.66% | $914.42M | 0.75% |
| MINT | 2.82% | $11.62B | 0.35% |
| XHLF | -3.56% | $874.27M | 0.03% |
News
Yahoo
The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Yahoo
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Yahoo
Market forces rained on the parade of Xencor, Inc. ( NASDAQ:XNCR ) shareholders today, when the analysts downgraded...
Yahoo
Xencor (XNCR) delivered earnings and revenue surprises of 27.55% and 38.41%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
PASADENA, Calif. AP) — Xencor Inc. XNCR) on Wednesday reported a loss of $45.1 million in its third quarter.
Yahoo
PASADENA, Calif., November 06, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third quarter ended September 30, 2024 and provided a review of recent business and clinical-stage program updates.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.